GlassScriptPhysician profile
Aria M Behrouzi
NPI 1114419025
$1,158.18
in general payments reported to CMS, 2019-2025
10 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $68.85 · 2021: $119 · 2022: $290 · 2023: $276 · 2024: $115 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $203.04 | 2023-2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $185.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $152.79 | 2019-2020 | |
| Abbvie INC. | $128.46 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.75 | 2021 | |
| Abbott Laboratories | $104.01 | 2022 | |
| Amgen INC. | $101.52 | 2023 | Repatha |
| Dexcom, INC. | $86.14 | 2023 | Dexcom G7 Gss (161) |
| E.R. Squibb & Sons, L.L.C. | $46.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $32.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aria Behrouzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.